These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6307874)

  • 1. Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice.
    Thomson TA; Hilfenhaus J; Moser H; Morahan PS
    Infect Immun; 1983 Aug; 41(2):556-62. PubMed ID: 6307874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
    Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
    J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines.
    Brynestad K; Babbit B; Huang L; Rouse BT
    J Virol; 1990 Feb; 64(2):680-5. PubMed ID: 2153234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of subviral herpes simplex virus type 1 preparation: protection of mice against intradermal challenge with type 1 and type 2 viruses.
    Slichtová V; Kutinová L; Vonka V
    Arch Virol; 1980; 66(3):207-14. PubMed ID: 6255896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
    Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
    J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral response to HSV-1 subunit vaccines--a statistical analysis.
    Simms JR; Heath AW; Richardson VJ; Jennings R
    Dev Biol Stand; 1998; 92():335-40. PubMed ID: 9554289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of recurrent herpes labialis using a herpes simplex Type-I subunit vaccine. A prospective randomized double-blind multicenter study].
    Altmeyer P; Wehrenberg O; Holzmann H; Paul E; Kimmig WK; Wassilew SW; Petres J; Korger G
    Hautarzt; 1991 Dec; 42(12):759-63. PubMed ID: 1662671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
    Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
    Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
    Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
    Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection.
    Wang C; Lu J; Du W; Wang G; Li X; Shen X; Su C; Yang L; Chen B; Wang J; Xu M
    Vaccine; 2019 Jul; 37(32):4477-4484. PubMed ID: 31266673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use.
    Burke RL
    Rev Infect Dis; 1991; 13 Suppl 11():S906-11. PubMed ID: 1664126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection.
    Rooney JF; Wohlenberg C; Cremer KJ; Notkins AL
    J Infect Dis; 1989 May; 159(5):974-6. PubMed ID: 2540251
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune responses to labial infection of BALB/c mice with herpes simplex virus type 1.
    Morahan PS; Thomson TA; Kohl S; Murray BK
    Infect Immun; 1981 Apr; 32(1):180-7. PubMed ID: 7216485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.